Evidence map›Paper›PMID 34659175›Full record

ArticleFrontiers in microbiology2021

First Report of

Xiangning Huang, Siquan Shen, Qingyu Shi, Li Ding, Shi Wu, Renru Han, Xun Zhou, Hua Yu, Fupin Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Review
  3. Coexistence ofFrontiers in microbiology · 2026
    Article
  4. Emergence of carbapenem-resistantMicrobiology spectrum · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Genomic characterization of two carbapenem-resistantFrontiers in cellular and infection microbiology · 2023
    Article
  10. PeerJ · 2023
    Review
  11. Occurrence ofAntibiotics (Basel, Switzerland) · 2022
    Article
  12. Characterization of the First Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
  13. Coexistence ofFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiangning HuangDepartment of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Siquan ShenHuashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China.
Qingyu ShiHuashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China.
Li DingHuashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China.
Shi WuHuashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China.
Renru HanHuashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China.
Xun ZhouHuashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China.
Hua YuDepartment of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Fupin HuHuashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China.
Huashan Hospital · CNFudan University · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-resistant

Indexed as

blaIMP–4blaSRT–2class 1 integronIncN plasmidSerratia marcescens

Identifiers

PMID34659175
PMCPMC8517538
OpenAlexW3202613292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.